目的 探讨年轻恶性肿瘤化疗女性的发病情况及保留生育功能和卵巢功能的意义。方法 回顾性分析和总结在我院行化疗的17～40岁年轻恶性肿瘤女性患者的年龄、肿瘤类别、构成等临床资料。结果 5年间在我院化疗的1261例女性恶性肿瘤患者中,年龄15～40岁者共786例(占62.3％),其中乳腺癌355例、大肠癌89例、白血病80例、宫颈癌67例、卵巢癌46例、恶性淋巴瘤39例,胃癌38例,肺癌30例,肝癌18例。15～25岁年龄段的女性恶性肿瘤化疗以白血病和卵巢癌为主。随年龄增长,大部分女性恶性肿瘤化疗的发生率增高。结论 15～40岁年轻恶性肿瘤化疗女性中乳腺癌占首位,其次为大肠癌、白血病和宫颈癌。保留年轻患者卵巢功能和生育功能的保守治疗具有重要意义。

Objective To analyze the clinical characteristics of malignant tumor in young women receiving chemotherapy aged from 15 to 40 and investigate the role of conservative treatment. Methods The clinical data of female aged from15 to 40 years old who were received chemotherapy in our hospital between 2010 and 2014 were retrospectively analyzed. Results 786 cases were identified from 1261 cases of malignant tumor receiving chemotherapy. Including 355 cases of breast cancer,89 cases of colorectal cancer,80 cases of leukemia,67 cases of cervical carcinoma,46 cases of ovarian cancer,39 cases of lymphoma,38 cases of gastric cancer,30 cases of lung cancer and 18 cases of liver cancer. Leukemia and ovarian cancer is the most common malignant tumor in young female between 15 to 25 years old. The cases of malignant tumor receiving chemotherapy increased with increasing age. Conclusion Breast cancer is the most common malignant tumor in young female receiving chemotherapy, followed by colorectal cancer, leukemia, and cervical carcinoma. It is very important to conserve young women's ovary function and fertility function.

        放射治疗（放疗）可以提高妇科恶性肿瘤患者的总体生存率，降低复发率，增加手术机会。但肿瘤周围的健康组织不可避免地会进入电离辐射区域从而导致阴道狭窄、缩短和失去弹性，文章结合近年来国内外的放疗后阴道损伤治疗方式进行综述，总结分析治疗的优缺点，旨在为放疗后阴道损伤的临床治疗提供帮助。

       Radiotherapy can improve the overall survival rate，reduce the  recurrence  rate and increase the chance of surgery in patients with gynecological malignant tumors．However，the healthy tissue around the tumor can inevitably be included the ionizing radiation area，resulting in vaginal stenosis，shortening and loss of elasticity．This paper reviews the treatment methods of post-radiotherapy vaginal injury at home and abroad in recent years，to summarize and analyze theadvantages and disadvantages of treatment，aiming to provide help for the clinical treatment of post-radiotherapy vaginal injury．

      长链非编码RNA（lncRNA）是一类长度大于200个核苷酸转录本，通过调控DNA、RNA及蛋白质的表达和功能，参与肿瘤发生、发展并发挥重要作用的RNA，近年来lncRNA成为恶性肿瘤早期诊断和预后标志物研究新的关注方向。Linc-UBC1作为一种新发现的lncRNA，在多种恶性肿瘤如肺癌、胃癌、结直肠癌、宫颈癌、卵巢癌、食管鳞癌等中异常高表达，可通过作为竞争性RNA（ceRNA）、参与信号通路等促进肿瘤细胞的增殖、迁移、侵袭、细胞周期进展、细胞凋亡和上皮间充质转化（EMT）等过程；高表达的linc-UBC1能够增加恶性肿瘤的耐药性，其表达水平与肿瘤分期、淋巴结转移和原发肿瘤远处转移呈正相关；linc-UBC1有望成为许多恶性肿瘤的新型的生物标志物、预后预测因子和治疗靶点，但其具体的调控机制仍处于研究的早期阶段，有待进一步深入研究。文章就目前linc-UBC1在恶性肿瘤发生和发展中的作用研究进展进行综述。

       Long non-coding RNA（lncRNA）is a class of transcripts with a length of more than 200 nucleotides．It is 

involved in the occurrence and development of tumors and plays an important role by regulating the expression and function of DNA，RNA and protein．In recent years，lncRNA has become a new research direction for early diagnosis and prognosis of malignant tumors．As a newly discovered lncRNA，linc-UBC1 is abnormally highly expressed in a variety of malignant tumors such as lung cancer，gastric cancer，colorectal cancer，cervical cancer，ovarian cancer，and esophageal squamous cell carcinoma．It can  promote the proliferation，migration，invasion，cell cycle progression，cell apoptosis and EMT of tumor cells by acting as a competing endogenous RNA（ceRNA）and participating in signaling pathways．High expression of linc-UBC1 can increase the drug resistance of malignant tumors，and its expression level is positively correlated with tumor stage，lymph node metastasis and distant metastasis of primary tumors．linc-UBC1 is expected to become a new biomarker，prognostic predictor and therapeutic target for many malignant tumors，while its specific regulatory mechanism is still in the early stage of research and needs further in-depth study．This article reviews the current research progress of linc-UBC1 in the occurrence and development of malignant tumors．